SEC Filing Summary: Stellar Biotechnologies, Inc.
Business Context and Reporting Period
This Form 8-K was filed on March 29, 2016, by Stellar Biotechnologies, Inc., a company incorporated in British Columbia, Canada, with principal executive offices in Port Hueneme, California. The filing reports a corporate event occurring on the same date.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a corporate governance event rather than financial performance.
Material Changes
The primary material change reported is the effective date of the Company's voluntary delisting of its common shares (no par value per share) from the TSX Venture Exchange.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, or specific risk factors beyond the implications of the delisting event. A press release dated March 29, 2016, is incorporated by reference as Exhibit 99.1 for further details.
Investor Verification Checklist
- Verify the current trading status of Stellar Biotechnologies, Inc. common shares following the TSX Venture Exchange delisting.
- Review the full text of the press release (Exhibit 99.1) for the rationale behind the voluntary delisting.
- Confirm if the company has listed its shares on an alternative exchange or is trading over-the-counter.
- Check for subsequent filings regarding the company's operational status post-delisting.